Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

562 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Endometrial Cancer Lymphadenectomy Trial (ECLAT) (pelvic and para-aortic lymphadenectomy in patients with stage I or II endometrial cancer with high risk of recurrence; AGO-OP.6).
Emons G, Kim JW, Weide K, de Gregorio N, Wimberger P, Trillsch F, Gabriel B, Denschlag D, Kommoss S, Aydogdu M, Papathemelis T, Gropp-Meier M, Muallem MZ, Kühn C, Müller A, Frank M, Weigel M, Bronger H, Lampe B, Rau J, Schade-Brittinger C, Harter P. Emons G, et al. Among authors: harter p. Int J Gynecol Cancer. 2021 Jul;31(7):1075-1079. doi: 10.1136/ijgc-2021-002703. Int J Gynecol Cancer. 2021. PMID: 34226291 Clinical Trial.
Histological grading in a large series of advanced stage ovarian carcinomas by three widely used grading systems: consistent lack of prognostic significance. A translational research subprotocol of a prospective randomized phase III study (AGO-OVAR 3 protocol).
Kommoss S, Schmidt D, Kommoss F, Hedderich J, Harter P, Pfisterer J, du Bois A. Kommoss S, et al. Among authors: harter p. Virchows Arch. 2009 Mar;454(3):249-56. doi: 10.1007/s00428-009-0725-y. Epub 2009 Jan 27. Virchows Arch. 2009. PMID: 19172293
Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany.
Pfisterer J, Du Bois A, Bentz EK, Kommoss F, Harter P, Huober J, Schmalfeldt B, Burchardi N, Arnold N, Hilpert F. Pfisterer J, et al. Among authors: harter p. Int J Gynecol Cancer. 2009 Jan;19(1):109-15. doi: 10.1111/IGC.0b013e3181991a7c. Int J Gynecol Cancer. 2009. PMID: 19258951 Clinical Trial.
Role of cytoreductive surgery in recurrent ovarian cancer.
Harter P, Hilpert F, Mahner S, Kommoss S, Heitz F, du Bois A. Harter P, et al. Expert Rev Anticancer Ther. 2009 Jul;9(7):917-22. doi: 10.1586/era.09.49. Expert Rev Anticancer Ther. 2009. PMID: 19589031 Review.
Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group).
Wimberger P, Wehling M, Lehmann N, Kimmig R, Schmalfeldt B, Burges A, Harter P, Pfisterer J, du Bois A. Wimberger P, et al. Among authors: harter p. Ann Surg Oncol. 2010 Jun;17(6):1642-8. doi: 10.1245/s10434-010-0964-9. Epub 2010 Feb 18. Ann Surg Oncol. 2010. PMID: 20165986
Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials.
du Bois A, Reuss A, Harter P, Pujade-Lauraine E, Ray-Coquard I, Pfisterer J; Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom; Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. du Bois A, et al. Among authors: harter p. J Clin Oncol. 2010 Apr 1;28(10):1733-9. doi: 10.1200/JCO.2009.25.3617. Epub 2010 Mar 1. J Clin Oncol. 2010. PMID: 20194855
562 results